# Concurrent Azeliragon With Craniospinal Irradiation

> **NCT06724926** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **NYU Langone Health** · enrollment: 21 (actual)

## Conditions studied

- Solid Tumor
- High-grade Glioma
- Leptomeningeal Metastasis

## Interventions

- **DRUG:** Azeliragon
- **PROCEDURE:** CSI

## Key facts

- **NCT ID:** NCT06724926
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-18
- **Primary completion:** 2027-01
- **Final completion:** 2031-01
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06724926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06724926, "Concurrent Azeliragon With Craniospinal Irradiation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06724926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*